Mark Breidenbach
Stock Analyst at Oppenheimer
(1.29)
# 3,664
Out of 5,090 analysts
52
Total ratings
30.91%
Success rate
-0.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $1.43 | +389.51% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $17.97 | +66.94% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $12.83 | +640.74% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $6.50 | +284.62% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.55 | +1,718.51% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $16.90 | +1,320.12% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $3.37 | +4,647.77% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $1.55 | +353.07% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.88 | +1,606.67% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $2.23 | +572.65% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $120 | $1.09 | +10,909.17% | 4 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $1.29 | +758,182.78% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $1.43
Upside: +389.51%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $17.97
Upside: +66.94%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $12.83
Upside: +640.74%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $6.50
Upside: +284.62%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.55
Upside: +1,718.51%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $16.90
Upside: +1,320.12%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $3.37
Upside: +4,647.77%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $1.55
Upside: +353.07%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.88
Upside: +1,606.67%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $2.23
Upside: +572.65%
Oct 18, 2022
Maintains: Outperform
Price Target: $90 → $120
Current: $1.09
Upside: +10,909.17%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $1.29
Upside: +758,182.78%